Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

A Unique Mycoplasma Protein Generically Binds All Types of Antibodies and Blocks Antigen Binding

By BiotechDaily International staff writers
Posted on 20 Feb 2014
Print article
Image: Protein M, an unusual bacterial protein, attaches to virtually any antibody, possibly helping bacteria establish long-term infections. Compared to thousands of known structures, this protein appears to be unique (Photo courtesy of the Scripps Research Institute).
Image: Protein M, an unusual bacterial protein, attaches to virtually any antibody, possibly helping bacteria establish long-term infections. Compared to thousands of known structures, this protein appears to be unique (Photo courtesy of the Scripps Research Institute).
A team of molecular biologists has isolated a bacterial protein that binds to all types of antibodies and prevents them attaching to their specific antigens.

The novel protein—Protein M—may join the ranks of other nonspecific antibody binding proteins such as Protein A and Protein G as a tool for researchers seeking to purify antibodies from mixtures of other biological molecules.

Investigators at The Scripps Research Institute (La Jolla, CA, USA) discovered Protein M, which was being produced by the primitive bacterium Mycoplasma genitalium, during a study on the relationship between chronic bacterial infection and myeloma.

After isolating the protein, the investigators used X-ray crystallography and other techniques, including electron microscopy, to determine Protein M's three-dimensional atomic structure while the protein was bound to various human antibodies. They reported in the February 7, 2014, issue of the journal Science that the crystal structure of the external domain of transmembrane Protein M differed from other known protein structures, as did its mechanism of antibody binding. Protein M bound with high affinity to all types of human and nonhuman immunoglobulin G, predominantly through attachment to the conserved portions of the variable region of the kappa and gamma light chains. Furthermore, Protein M blocked antibody-antigen binding, likely because of its large C-terminal domain extending over the antibody-combining site, blocking entry to large antigens.

The investigators suggested that the most immediate use for Protein M will likely be as a tool for immobilizing antibodies in mixtures and cell cultures as a preparatory step in the generation of highly purified antibodies for research and drug manufacturing. “It may be the most useful antibody purification device ever found,” said senior author Dr. Richard A. Lerner, professor of immunochemistry at The Scripps Research Institute.

Related Links:

The Scripps Research Institute



Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.